Cytogenetic analysis of de novo CD5-positive diffuse large B-cell lymphoma

Asia-Pacific Journal of Clinical Oncology

Volumn 7, Issue 4, 2011, Pages 346-350

  Kaneko, Hiroto ^a   Shimura, Kazuho ^a   Horiike, Shigeo ^b   Kuroda, Junya ^b   Matsumoto, Yosuke ^b   Yokota, Shohei ^b   Nishida, Koichi ^a   Ohkawara, Yasuo ^a   Taniwaki, Masafumi ^b  

^a Aiseikai Yamashina Hospital   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Breakpoint; CD5; Chromosome; Diffuse large B cell lymphoma; Rearrangement

Indexed keywords

CD5 ANTIGEN; COLCHICINE; TRYPSIN;

ADULT; AGED; ARTICLE; CHROMOSOME ANALYSIS; CHROMOSOME BREAKAGE; CHROMOSOME LOSS; CHROMOSOME REARRANGEMENT; CLINICAL ARTICLE; FEMALE; GENETIC ANALYSIS; GIEMSA STAIN; HUMAN; HUMAN CELL; KARYOTYPE; LARGE CELL LYMPHOMA; MALE; METAPHASE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TUMOR CELL CULTURE;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD5; CHROMOSOME ABERRATIONS; CYTOGENETIC ANALYSIS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KARYOTYPE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; SURVIVAL ANALYSIS;

EID: 83355175826     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/j.1743-7563.2011.01432.x     Document Type: Article

References (22)

1. Yamaguchi M, Seto M, Okamoto M etal. De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood 2002; 99: 815-21.
2. Coiffier B, Lepage E, Briere J etal. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-42.
3. Pfreundschuh M, Trumper L, Osterborg A etal. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomized controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379-91.
4. Ennishi D, Takeuchi K, Yokoyama M etal. CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. Ann Oncol 2008; 19: 1921-6.
5. Niitsu N, Okamoto M, Tamaru JI etal. Clinicopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5-positive in comparison with CD5-negative diffuse large B-cell lymphoma. Ann Oncol 2010; 21: 2069-74.
6. Miyazaki K, Yamaguchi M, Suzuki R etal. CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximab. Ann Oncol 2011; Epub ahead of print.
7. Tagawa H, Suguro M, Tsuzuki S etal. Comparison of genome profiles for identification of distinct subtypes of diffuse large B-cell lymphoma. Blood 2005; 106: 1770-7.
8. Hans CP, Weisenburger DD, Greiner TC etal. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-82.
9. Rosenwald A, Wright G, Chan WC etal. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937-47.
10. Katzenberger T, Lohr A, Schwarz S etal. Genetic analysis of de novo CD5+ diffuse large B-cell lymphomas suggests an origin from a somatically mutated CD5+ progenitor B cell. Blood 2003; 101: 699-702.
11. Yoshioka T, Miura I, Kume M etal. Cyotogenetic features of de novo CD5-positive diffuse large B-cell lymphoma: chromosome aberrations affecting 8p21 and 11q23 constitute major subgroups with different overall survival. Genes Chromosomes Cancer 2005; 42: 149-57.
12. Misawa S, Horiike S, Taniwaki M, Abe T, Takino T. Prefixation treatment with ethidium bromide for high resolution banding of chromosomes from cultured human bone marrow cells. Cancer Genet Cytogenet 1986; 22: 319-29.
13. Mitelman F, ed. An International System for Human Cytogenetic Nomenclature. Karger, Basel 1995.
14. Yunis JJ, Oken MM, Theologides A, Howe RB, Kaplan ME. Recurrent chromosomal defects are found in most patients with non-Hodgkin's lymphoma. Cancer Genet Cytogenet 1984; 13: 17-28.
15. Rowley JD. Identification of the constant chromosome regions involved in human hematologic malignant disease. Science 1982; 216: 749-51.
16. Horsman D, Gascoyne R, Klasa R, Coupland R. t(11;18)(q21;q21.1): a recurring translocation in lymphomas of mucosa-associated lymphoid tissue (MALT)? Genes Chromosomes Cancer 1992; 4: 183-7.
17. Rodriguez MA, Ford RJ, Goodacre A, Selvanayagam P, Cabanillas F, Deisseroth AB. Chromosome 17- and p53 changes in lymphoma. Br J Haematol 1991; 79: 575-82.
18. Young KH, Leroy K, Møller MB etal. Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. Blood 2008; 112: 3088-98.
19. Tagawa H, Tsuzuki S, Suzuki R etal. Genome-wide array-based comparative genomic hybridization of diffuse large B-cell lymphoma. Comparison between CD5-positive and CD5-negative cases. Cancer Res 2004; 64: 5948-55.
20. Karnan S, Tagawa H, Suzuki R etal. Analysis of chromosomal imbalances in de novo CD5-positive diffuse large B-cell lymphoma detected by comparative genomic hybridization. Genes Chromosomes Cancer 2004; 39: 77-81.
21. Yamaguchi M, Nakamura N, Suzuki R etal. De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients. Haematologica 2008; 93: 1195-202.
22. - diffuse large B-cell lymphomas. Cancer Res 2003; 63: 60-6.